Astellas Signs an Exclusive License Agreement with Pandion to Deliver Immunomodulators for Autoimmune Diseases of the Pancreas

 Astellas Signs an Exclusive License Agreement with Pandion to Deliver Immunomodulators for Autoimmune Diseases of the Pancreas

Astellas Signs an Exclusive License Agreement with Pandion to Deliver Immunomodulators for Autoimmune Diseases of the Pancreas

Shots:

  • Pandion to receive up to $45M as upfront and payments for research and preclinical activities, ~$750M as development and commercial milestone and royalties on global sales of the therapies developed via collaboration
  • Pandion to be responsible for drug designing and discovery of bispecific therapies utilizing its modular immune effector and tissue tether platform while Astellas will be responsible for pre/clinical and commercialization activities of the selected candidates developed during the collaboration
  • The collaboration will leverage Pandion’s modular biologics and functional immunology expertise with Astellas’ development and global commercialization capabilities for the treatment of autoimmune diseases

Click here to­ read full press release/ article | Ref: Business wire | Image: EK Magazine

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post